Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

Qianqian Zhao, Gang Chen, Luxi Ye, Shiming Shi, Shisuo Du, Zhaochong Zeng* and Jian He*

Abstract

Background: To investigate the potential impact of fractionation regimes and overall treatment time (OTT) on lymphopenia during definitive radiotherapy (RT) and its associations with patient outcomes in non-small cell lung cancer (NSCLC).

Methods: Subjects consisted of 115 patients who had received definitive chemoradiation therapy (CRT) with different doses and fractions for unresectable stage III NSCLC. Clinical and laboratory records were reviewed to assess the changes in total lymphocyte counts (TLCs) during definitive RT. The associations of the TLCs with the clinical and treatment features, and outcomes were analyzed.

Results: The median reduction of TLCs in the entire cohort was 1300 cells/μL (interquartile range [IQR], 950–1510 cells/μL). Of all patients, 63 (54.8%) experienced severe lymphopenia (SL) (TLC nadir < 500 cells/μL), which occurred at a median of the 5th week following RT initiation, not at the completion of RT or upon treatment with maximal doses. SL risk was increased over the first 5 weeks (odds ratio [OR] = 3.455, P = 0.007), after which, no increased risk was observed (OR = 0.562, P = 0.216). The median TLCs remained low and failed to recover to the initial normal values of their pre-RT level after 2 months of RT completion. Patients without SL exhibited significantly improved progression-free survival (hazard ratio [HR] = 0.544, P = 0.010) and overall survival (HR = 0.463, P = 0.011) after controlling for confounding variables in multivariate analyses. The incidence of SL was significantly lower (71.1% reduction in risk (OR = 0.289, P = 0.007)) in patients who received hypofractionated RT with an OTT within 4 weeks, compared to those who had an OTT of more than 4 weeks (32.1% vs 62.1%, P = 0.006). Multivariate analyses revealed that OTT within 4 weeks (OR = 0.322, P = 0.032) was significantly associated with a decreased risk of developing SL after controlling for confounding factors.

Conclusions: Hypofractionated RT was significantly associated with a decreased risk of SL and improved survival during definitive radiotherapy for unresectable stage III NSCLC.

Keywords: Non-small cell lung cancer, Total lymphocyte counts, Fractionation regimes, Overall treatment time
Background
Definitive radiotherapy (RT) with platinum-based doublet chemotherapy has been widely recognized over the past few decades as the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, the survival outcomes with this approach remain disappointing, with a 5-year overall survival (OS) rate of approximately 15% using conventionally-fractionated radiotherapy (CFRT) with doses of 60–66 Gy in 30–33 fractions [1, 2]. As promising results were observed in the PACIFIC trial, consolidation treatments with immune checkpoint inhibitors (ICIs) are now recommended for patients with stage III, unresectable NSCLC after receiving definitive CRT [3]. However, on the basis of CFRT, increasing the number of fractions and radiation duration to increase the overall radiation dose did not improve outcomes for patients [4]. With higher biological effective dose (BED) over a shorter period, hypofractionated radiotherapy (HFRT) could overcome the accelerated repopulation of tumor cells during treatment and theoretically obtain better efficacies [5, 6]. However, the clinical application of HFRT has been limited due to the side effects of irradiation, particularly grade III or IV toxicities [6]. In recent years, advances in RT techniques have facilitated the safe and effective delivery of high doses of radiation to tumors while preserved the surrounding disease. Several studies reported that HFRT could achieve good local control with well-tolerated toxicity for locally-advanced NSCLC when modern RT techniques were utilized [7–9]. HFRT is experiencing increasing importance in the treatment of locally-advanced NSCLC.

Numerous studies demonstrated that the host immune system and peripheral lymphocyte populations play crucial roles in oncologic outcomes, and the reduction in total peripheral lymphocyte counts (TLCs) results in impairing antitumor immunity [10, 11]. Lymphopenia is a common consequence of RT in cancer patients, regardless of whether other lymphotoxic agents, such as corticosteroids or cytotoxic chemotherapeutics are administered [12–15]. The preclinical model suggested that decreasing the target radiation volume and fraction size significantly reduced the circulating blood exposure radiation dose [16]. It is therefore possible that protracted radiation courses with higher fractions will increase exposures to radiation and increase lymphocyte destruction. Such assumptions have led some researchers to conclude that HFRT with shorter treatment periods would reduce radiation exposure dose to circulating blood and spare peripheral lymphocytes, compared to CFRT with treatment period extending.

Despite theoretical superiority, the impact of different fractionation regimes and overall treatment times (OTT) on radiation-induced lymphopenia (RIL) in unresectable stage III NSCLC was largely unexplored until recently. In our institution, apart from CFRT, other fractionation regimes with increased doses per fraction and shorter OTT have been increasingly adopted since 2011 for locally advanced NSCLC. Therefore, we sought to evaluate the potential impact of fraction regime and OTT on TLCs by retrospectively analyzing stage III, locally advanced, unresectable NSCLC patients receiving definitive chemoradiation therapy (CRT) at our institution.

Methods
Patient population
After approval by the institutional review board, we retrospectively analyzed the medical records of consecutive patients with histologically-verified NSCLC receiving definitive CRT (equivalent dose in 2 Gy fraction [EQD2] ≥ 60 Gy, whereas the α/β ratio for lung cancer is 10 Gy [16]) at Zhongshan Hospital, Fudan University from January 2011 to December 2017. All patients were (re)staged according to the 8th edition of the AJCC TNM classification. The inclusion criteria were as follows: (1) unresectable Stage III NSCLC (2) age 18 years or above and an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; (3) no history of a concomitant malignancy; (4) no prior RT or immunotherapy for any disease; (5) finished the scheduled treatment including four or more cycles of platinum-based doublet chemotherapy; (6) complete and retrievable medical records, including at least 3 documented weekly TLCs values during RT course were available for review. Patients were excluded if they had received any other anticancer treatments besides CRT before disease progression, had used any systemic corticosteroids during RT except for pretreatment before chemotherapy, had any ongoing infection, rheumatoid disease, and had immune system disease. All patients underwent a comprehensive assessment within 3 weeks prior to the treatment, including routine blood testing, pulmonary function tests, chest/abdominal CT with contrast, brain magnetic resonance imaging, abdominal ultrasonography, bone scan, and/or positron emission tomography/computed tomography (PET/CT). Informed consent was obtained from all patients.

Therapeutic interventions
Treatment planning, including radiation targets, normal tissue dose constraints, and delivery techniques for locally advanced NSCLC in our institution have been previously described [8]. The fractionation regimes primarily depended on the treating physicians’ preference, based on the clinical tumor size and location. Typically, 2.0 to 3.0 Gy per fraction for 20–30 fractions, and a total dose of 60–70 Gy were adopted in our institution. The fractionation regimes information used in our study population were shown in Table 1. The median calculated BED was 76.8 Gy (interquartile range [IQR] 72.0–78.0 Gy), whereas
the α/β ratio for lung cancer is 10 Gy [17], and the median EQD2 was 64.0 Gy (IQR, 60.0–65.0 Gy).

Data acquisition
Clinical and laboratory parameters were extracted from the electronic medical record for all patients. Patient-specific variables included age, sex, ECOG performance status, smoking history, and baseline laboratory values. Tumor-specific variables included histological type and TNM classification. Treatment-specific variables included the RT technique, dose per fraction, fractions, treatment interruption, receipt of chemotherapy, chemotherapy type, and chemotherapy timing. Dosimetric parameters included gross target volume (GTV), planning target volume (PTV), mean dose to lung (MLD) and heart (MHD), and percentage volume of lung and heart receiving 5–60 Gy (V5–60 Gy) in 5 Gy increments, respectively.

TLCs were collected and investigated at the following intervals: within 2 weeks prior to induction chemotherapy or RT (baseline TLCs), within 2 weeks prior to the start of RT (Pre-RT TLCs), weekly during radiation treatment, and 1 and 2 months after RT completion. If complete blood cell counts were not available at the exact time point, i.e. no TLCs data were recorded for that time point. TLCs nadir was defined as the minimum value of TLCs during the course of RT. Severe lymphopenia (SL) was defined as TLCs nadir below 500 cells/μL during the course of RT, consistent with grade 3 toxicity according to the Common Terminology Criteria for Adverse Events version 5.0.

Clinical follow-up was generally conducted every 3 months for the first year, every 6 months for the next 2 years, and yearly thereafter. Follow-up examinations included physical examinations, blood tests, chest CT scans, and/or PET/CT. Further examinations were performed when needed for clinical purposes. Progression-free survival (PFS) was calculated from the date of pathologic diagnosis to the date of disease progression, death or last follow-up. OS was calculated from the date of pathologic diagnosis to the date of death from any cause or last follow-up. Patients were censored at the date of the last available follow-up if alive and the data were updated in October 2018.

Statistical analysis
Patients, tumor, and treatment characteristics for the entire group and patient subgroups were summarized using descriptive statistics. To visualize trends in TLCs over the course of RT, TLCs were plotted versus RT time (weeks). Chi-squared and non-parametric tests were used to compare the differences in proportions or medians between groups. Survival rates were calculated using the Kaplan-Meier method, and comparisons were made using the log-rank test. Prognostic variables with p-values ≤0.2 on univariate analyses were entered as covariates in the multivariable Cox proportional hazards model using backward stepwise selection. Spearman correlations were used to examine correlations between dosimetric parameters and TLC nadir. Receiver operating characteristic (ROC) curve analyses were used to determine the optimal cut-off points for continuous variables identified as influencing SL. Univariate logistic regression analyses were conducted to identify variables potentially associated with an increased risk of SL. Multivariate stepwise logistic regression (using variables with univariate significance of p ≤ 0.2) were performed to assess the independent effect of such factors on the development of SL. In addition, age, sex, and ECOG performance status were retained in the initial multivariable model owing to their perceived clinical significances. All statistical analyses were conducted using IBM SPSS software version 23.0 (SPSS Inc., Chicago, IL, USA). Statistical tests were two-sided, and a p-value < 0.05 was considered statistically significant.

Results
Patient characteristics
A total of 115 patients met the inclusion criteria and were enrolled in the study. Baseline demographic, tumor, and treatment characteristics of all eligible patients are listed in Table 2. The median number of chemotherapy cycles was six (interquartile range [IQR], 4–6 cycles). Concurrent CRT regimens were given to 31 patients

| Table 1 Details of fractionation regimes used in our study population (n = 115) |
|---------------------------------------------------------------|
| Fractionation regime          | No. of cases (%) |
| 6000 cGy/20 fractions        | 30 (25.1%)       |
| 5940 cGy/22 fractions        | 2 (1.7%)         |
| 6300 cGy/23 fractions        | 1 (0.9%)         |
| 6000 cGy/24 fractions        | 1 (0.9%)         |
| 6240 cGy/24 fractions        | 1 (0.9%)         |
| 6000 cGy/25 fractions        | 11 (9.6%)        |
| 6100 cGy/25 fractions        | 1 (0.9%)         |
| 6250 cGy/25 fractions        | 9 (7.8%)         |
| 6400 cGy/25 fractions        | 1 (0.9%)         |
| 6500 cGy/25 fractions        | 1 (0.9%)         |
| 7000 cGy/25 fractions        | 1 (0.9%)         |
| 6240 cGy/26 fractions        | 1 (0.9%)         |
| 6210 cGy/27 fractions        | 4 (3.5%)         |
| 6160 cGy/28 fractions        | 5 (4.3%)         |
| 6000 cGy/30 fractions        | 30 (26.1%)       |
| 6400 cGy/32 fractions        | 8 (7.0%)         |
| 6600 cGy/33 fractions        | 6 (5.2%)         |
| 7000 cGy/35 fractions        | 2 (1.7%)         |

Note: The prescribed doses were given to gross tumor volume.
Table 2: Baseline patient, tumor, and treatment characteristics for all patients (n = 115) and broken down by patients did or did not experience SL.

| Characteristic                        | Total (N = 115) | SL (N = 63) | No SL (N = 52) | P value |
|---------------------------------------|-----------------|-------------|----------------|---------|
| Age at diagnosis, years, Median (IQR) | 63.00 (59.00–67.00) | 63.00 (60.00–67.00) | 62.50 (55.50–67.00) | 0.362   |
| Sex                                   |                 |             |                |         |
| Male                                  | 107 (92.2%)     | 59 (51.3%)  | 48 (41.7%)     |         |
| Female                                | 8 (7.0%)        | 4 (3.5%)    | 4 (3.5%)       | 0.778   |
| ECOG performance status               |                 |             |                |         |
| 0–1                                   | 84 (73.0%)      | 44 (38.3%)  | 40 (34.8%)     |         |
| 2                                     | 31 (27.0%)      | 19 (16.5%)  | 12 (10.4%)     | 0.394   |
| Smoking pack-years                    |                 |             |                |         |
| ≥ 10                                   | 80              | 45          | 35             |         |
| 0–10                                  | 4               | 3           | 1              |         |
| 0                                     | 24              | 12          | 12             |         |
| Unknown                               | 7               | 3           | 4              | 0.717   |
| Histology                             |                 |             |                |         |
| Squamous carcinoma                    | 78 (67.8%)      | 49 (42.2%)  | 35 (30.4%)     |         |
| Adenocarcinoma                        | 34 (29.6%)      | 19 (16.5%)  | 15 (13.0%)     |         |
| Others                                | 3 (2.6%)        | 1 (0.9%)    | 2 (1.7%)       | 0.683   |
| cT stage (AJCC 8th ed)                |                 |             |                |         |
| T1                                    | 14 (12.2%)      | 8 (7.0%)    | 6 (5.2%)       |         |
| T2                                    | 31 (26.7%)      | 20 (17.2%)  | 11 (9.5%)      |         |
| T3                                    | 27 (23.5%)      | 12 (10.4%)  | 15 (13.0%)     |         |
| T4                                    | 43 (37.4%)      | 23 (20.0%)  | 20 (17.4%)     | 0.492   |
| cN stage                              |                 |             |                |         |
| N1                                    | 6 (5.2%)        | 2 (1.7%)    | 4 (3.5%)       |         |
| N2                                    | 73 (63.5%)      | 39 (33.9%)  | 34 (29.6%)     |         |
| N3                                    | 36 (31.3%)      | 22 (19.1%)  | 14 (12.2%)     | 0.417   |
| Stage                                 |                 |             |                |         |
| IIIA                                  | 33 (28.7%)      | 18 (15.7%)  | 15 (13.0%)     |         |
| IIIB                                  | 61 (53.0%)      | 33 (28.7%)  | 28 (24.3%)     |         |
| IIIC                                  | 21 (18.3%)      | 12 (10.4%)  | 9 (7.8%)       | 0.971   |
| TLCs, cells/μL (median, IQR)          |                 |             |                |         |
| Baseline                              | 1600 (1400–2000)| 1600 (1300–1900)| 1800 (1400–2200)| 0.037   |
| Pre-RT                                | 1800 (1400–2100)| 1600 (1280–1900)| 1965 (1700–2252)| < 0.001 |
| TLC nadir during the course of RT     | 500 (380–700)   | 390 (300–470)| 700 (600–830)  | < 0.001 |
| 1 month after RT                      | 915 (700–1100)  | 800 (598–1100)| 995 (882–1232) | 0.004   |
| 2 month after RT                      | 900 (700–1100)  | 740 (600–982) | 1000 (810–1195)| < 0.001 |
| Tumor volume, cm³ (median, IQR)       |                 |             |                |         |
| GTV                                    | 56.85 (32.47–129.35)| 87.69 (45.58–144.92)| 43.40 (21.84–95.52)| 0.006   |
| PTV                                    | 146.03 (74.20–247.39)| 160.95 (80.69–258.92)| 124.82 (71.13–224.05)| 0.192   |
| EQD2 (Gy or Gy[RBE]) (median, IQR)    | 64.00 (60.00–65.00)| 62.87 (60.00–65.10)| 65.00 (60.00–65.00)| 0.755   |
| BED (Gy)                               | 76.80 (72.00–78.00)| 75.44 (72.00–78.13)| 78 (72–78)      | 0.768   |
| Fractions, number (median, IQR)       | 25 (20–30)      | 25 (25–30)  | 25 (20–30)     | 0.141   |
| OTT, days (median, IQR)               | 39 (31–43)      | 39 (33–43)  | 35 (29–43)     | 0.281   |

Key mean normal tissue doses, cGy (median, IQR)
(27.0%), and sequential CRT were given to 84 patients (73.0%). Additional details are provided in (Additional file 1; Table S1). Approximate 80% patients had received induction chemotherapy and they all had the baseline TLCs data. All patients had the Pre-RT TLCs. During the RT duration, all patients had at least 3 documented weekly TLCs values available for review. In the follow-up duration, approximate 70% patients had the TLCs data at 1 month and 63% patients had the TLCs data at 2 months. No significant differences in the median TLC nadir existed between patients who received sequential or concurrent CRT (500 vs 560 cells/μL; P = 0.725). As noted in Table 2, the SL subset was significantly different from the non-SL subset in lower baseline TLCs, larger GTV, and higher radiation doses to the lungs and heart.

**TLCs trend over the time**

Figure 1 summarizes the changes in TLCs over time. The median pre-RT TLC was 1800 cells/μL (IQR, 1400–2100 cells/μL), which was within the normal range and was not different from the baseline level of 1600 cells/μL (IQR, 1400–2000 cells/μL) (P = 0.122). No differences in TLC changes were observed between chemotherapy subgroups, whether stratified by the chemotherapy regimen or cycles (all P > 0.05). As shown in Fig. 1, TLCs decreased from the beginning of RT, and declined steeply each week during the first 5 weeks before stabilizing. The median TLCs gradually declined to 1080, 885, 700, 600, 470, 600, and 660 cells/μL from weeks 1 to 7, respectively. The median TLC nadir in the entire cohort was 500 cells/μL (IQR, 380–700 cells/μL) and median reduction of TLCs was 1300 cells/μL (IQR, 950–1510 cells/μL). Of all patients, 63 (54.8%) experienced SL, which occurred at a median of the 5th week (IQR, 4–5 weeks) following RT initiation, not at the completion of RT or upon treatment with maximal doses. The SL risk increased over the first 5 weeks (odds ratio [OR] = 3.455, 95% CI, 1.399 to 8.528; P = 0.007), after which, risk no longer continued to increase (OR = 0.562, 95% CI, 0.216). After 2 months following RT, median TLCs remained low and failed to recover to their pre-RT levels. Patients who developed SL were more likely to continue to have persistent lymphopenia one to 2 months after RT (median: 800 vs 995 cells/μL, P = 0.004; median: 740 vs 1000 cells/μL, P < 0.001; respectively) (Table 2).

To better understand the impact of OTT on TLCs in patients, we divided patients into two groups based on changes in TLCs during RT: the short-term radiotherapy (STRT) group had an OTT of 4 weeks or less (<4 weeks), while the long-term radiotherapy (LTRT) group had an OTT of more than 4 weeks (≥4 weeks). Overall, 28 patients (24.3%) received STRT and 87 patients (75.7%) received LTRT. All patients in the STRT group received 60 Gy/20 fractions over a median of 26 days (IQR, 25–28 days), while those in the LTRT group received a median of 60 Gy (IQR, 60–62.50 Gy)/30 fractions (IQR, 25–30 fractions) over 41 days (36–44 days). The incidence of SL was significantly lower in patients who received STRT than in those receiving LTRT (32.1% vs 62.1%, P = 0.006), with a 71.1% reduction in risk (OR = 0.289, 95% CI, 0.117–0.715; P = 0.007).

**Table 2 Baseline patient, tumor, and treatment characteristics for all patients (n = 115) and broken down by patients did or did not experience SL (Continued)**

| Characteristic                      | Total (N = 115) | SL (N = 63) | No SL (N = 52) | P value |
|------------------------------------|----------------|------------|---------------|---------|
| Mean lung dose                     | 1275 (1078–1454)| 1354.90 (1146.00–1480.00) | 1165 (990–1386) | 0.007   |
| Mean heart dose                    | 601 (420–1261.50)| 886 (439.00–1502.25) | 518 (384–936.90) | 0.041   |
| Radiation technique                |                |            |               |         |
| 3D conformal                       | 28 (24.3%)     | 16 (13.9%) | 12 (10.4%)    |         |
| Intensity modulated                | 37 (32.2%)     | 19 (16.5%) | 18 (15.7%)    |         |
| Helical Tomotherapy                | 50 (43.5%)     | 28 (24.3%) | 22 (19.1%)    | 0.874   |
| Concurrent chemoradiation (sequential) |          |            |               |         |
| Yes                                | 31 (27.0%)     | 15 (12.9%) | 16 (13.9%)    |         |
| No                                 | 84 (73.0%)     | 48 (41.7%) | 36 (31.3%)    | 0.403   |
| Induction chemotherapy             |                |            |               |         |
| Yes                                | 91 (79.1%)     | 54 (47.0%) | 37 (32.2%)    |         |
| No                                 | 24 (20.9%)     | 9 (7.8%)   | 15 (13.0%)    | 0.056   |
| Adjuvant chemotherapy              |                |            |               |         |
| Yes                                | 61 (53.0%)     | 31 (27.0%) | 30 (26.1%)    |         |
| No                                 | 54 (47.0%)     | 32 (27.8%) | 22 (19.1%)    | 0.364   |

**Abbreviations:** SL severe lymphopenia, IQR interquartile range, ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, TLCs total peripheral lymphocyte counts, GTV gross tumor volume, PTV planning target volume, EQD2 equivalents (relative biological equivalents), BED biological effective dose, OTT overall treatment time
Survival

Eight patients were excluded from survival analyses due to incomplete follow-up data. Nearly half of the patients (n = 49) died during the follow-up period. The median follow-up period from diagnosis was 18 months (IQR, 14 to 26 months) and 20 months (IQR, 14 to 28.5 months) for patients alive at the last follow-up. The median PFS for the entire cohort (n = 107) was 11 months (95% CI, 10–12 months) and the median OS was 25 months (95% CI, 20–30 months).

Whether the TLC nadir was analyzed as a continuous variable or patients were divided into SL and non-SL groups, they were all associated with PFS (hazard ratio [HR] = 0.999, 95% CI, 0.998–1.000; P = 0.012 and HR = 0.524, 95% CI, 0.331–0.831; P = 0.006, respectively) and OS (HR = 0.999, 95% CI, 0.997–1.000; P = 0.013 and HR = 0.460, 95% CI, 0.255–0.831; P = 0.010, respectively). The median PFS was 10 months (95% CI, 8–12 months) in patients who experienced SL and 13 months (95% CI, 9–17 months) in those who did not (P = 0.003), while the OS was 23 months (95% CI, 15–31 months) and 34 months (95% CI, 21–47 months), respectively (P = 0.008) (Fig. 2a and b). The median PFS was 12 months (95% CI, 11–13 months) in the STRT group, and 11 months (95% CI, 9–12 months) in the LTRT group (P = 0.136), and the OS was 36 months (95% CI, 4–67 months) versus 24 months (95% CI, 15–33 months), respectively (P = 0.071) (Fig. 2c and d). As shown in Table 3, patients with non-SL were associated with longer PFS (HR = 0.544, 95% CI, 0.343–0.863, P = 0.010) and OS (HR = 0.463, 95% CI, 0.256–0.837, P = 0.011) after controlling for confounding variables in multivariate analyses.

Risk factors of SL

We further analyzed the association between TLC nadir and the dosimetric parameters of the lungs and heart (Additional file 2: Table S2). Because the parameters were all highly correlated with each other, we used ROC analyses to establish the best cut-off values and found that the mean lung dose (MLD) and heart V5 (the percentage of total heart volume receiving at least 5 Gy) were the best predictors of SL (area under the curve = 0.630 and 0.614, respectively) (Additional file 4: Figure S1). To avoid multicollinearity, MLD and heart V5 was included in the logistic regression analyses.

Considering the potential impact of other confounding factors on TLCs, including the aforementioned dosimetric parameters, we performed univariate and multivariate logistic analyses in the pooled cohort (Table 4). Specifically, univariate analyses showed that the development of SL was predictable by pre-RT TLCs (P < 0.001), GTV (P = 0.017), MLD (P = 0.013), Heart V5 (s = 0.016), and OTT (P = 0.007). On multivariate analysis, after controlling for confounding factors, greater GTV (OR = 6.909, 95% CI, 1.729–27.612; P = 0.006) and higher MLD (OR = 3.633, 95% CI, 1.349–9.787; P = 0.011) were significantly associated with an increased risk of developing SL, whereas higher pre-RT TLCs (OR = 0.998, 95% CI, 0.997–0.999; P < 0.001)
and STRT (OR = 0.322, 95% CI, 0.115–0.908; \(P = 0.032\)) treatment were associated with a decreased risk of SL.

Since the RT technique could confound the choice of fractionation, a subgroup multivariate analysis was also conducted for patients treated with helical tomotherapy (HT). Similar to the whole cohort, STRT (OR = 0.223, 95% CI, 0.056–0.887; \(P = 0.033\)) was significantly associated with a decreased risk of developing SL after controlling for confounding factors (Additional file 3: Table S3).

**Discussion**

Many studies have shown that RT can dramatically reduce TLCs, and that low TLC nadirs were correlated with poor survival in many solid tumors. Our results further suggested that the level of TLCs was related to the RT treatment duration for unresectable stage III NSCLC. TLCs declined steeply each week for the first 5 weeks, after which, TLCs nadir occurred at approximately the 5th week. Increasing the dose of radiation per fraction to deliver the entire RT regimen in 4 weeks could significantly lower the risk of developing SL. This is in line with a recent study suggesting that SBRT could decrease the severity of RIL compared to CFRT in locally advanced pancreatic cancer [18]. Finally, our results revealed a significantly reduced risk of disease progression and death in patients who did not experience SL during RT.

Radiation can suppress or stimulate the immune system. The contribution of lymphocytes to radiation-induced tumor control was shown in mouse models over 30 years ago [19], and more recently, the availability of T cell receptor (TCR)-transgenic mice made it possible to unequivocally demonstrate that radiation can induce priming of T cells to exogenous model antigens expressed by tumors [20, 21]. Those studies together with the demonstration that radiation induces immunogenic cell death [22], have provided proof that radiation can induce tumor-specific T cells. This study revealed an association between higher lymphocyte levels during treatment and better clinical outcomes. Maintaining an intact adaptive immune system during cancer therapy may be important for enhancing the effectiveness of cytotoxic therapies and improving cancer control. This may impact cancer recurrence by affecting the numbers of tumor-infiltrating lymphocytes, which correlates with the prognosis of multiple cancers [23, 24]. This is consistent with our observation that TLC nadir was associated with worse PFS and OS.

The clinical implications of our findings may also be more pronounced in the setting of the new therapeutic...
strategy of combining RT and immunotherapy in NSCLC patients. As promising results were observed in the PACIFIC trial, consolidation treatments with immune checkpoint inhibitors (ICIs) are now recommended for patients with stage III, unresectable NSCLC after receiving definitive CRT [16]. Previous work has shown that RIL would further compromise the therapeutic efficacies of ICIs through the loss of effector cells, which identify and destroy tumor cells [25, 26]. The efficacy of ICIs relies on the modulation of lymphocyte activity and are dependent on circulating lymphocyte counts [27]. SL at the onset of ICI was independently associated with poor survival [25]. This further emphasized the importance of preserving and maintaining circulating lymphocytes in the emerging era of clinical immunotherapies. Considering the potential therapeutic abilities of circulating lymphocyte populations, a hypofractionated regimen with fewer fractionations and shorter treatment course (within 4 weeks) may be a superior approach for combination with immunotherapies.

Pulmonary circulation is the main portion of the cardiovascular system in which oxygen-depleted blood is pumped away from the heart via the pulmonary artery. A separate system known as bronchial circulation also supplies blood to the tissues of the larger airways. Arteries are further divided into very fine capillaries, which are extremely thin-walled and cover the lung. Some tumors may also be adjacent to heart, thoracic aorta, and vein which are filled with blood. Thus, the distribution of low-dose irradiation could include part of the heart or large vessels. One proposed mechanism for RIL is via radiation exposure of the circulating blood pool, since lymphopenia occurs after irradiation of tissues, including breast and brain, which contain little bone marrow or lymphatic tissues, respectively [28, 29]. Peripheral blood lymphocytes are known to be extremely sensitive to
radiation despite mitotic inactivity [30]. Nevertheless, an unexpected finding of our study was that the TLC nadirs occurred at approximately the fifth week, not at the completion of RT or upon delivery of maximal doses. Multiple studies demonstrated that pretreatment with low doses of irradiation can induce resistance to damage from subsequent high doses of irradiation [31, 32]. Yovino et al. analyzed a modeled "typical" radiation plan for glioblastoma (60 Gy/30 fractions) and found that a single fraction caused 0.5 Gy exposure to 5% of all circulating blood cells. L. Basler et al. also regarded that the proportion of circulating lymphocytes exposed to at least 0.5 Gy was a surrogate parameter for radiation-induced immunosuppression [33]. The circulating blood dose appeared to depend on the target volume and fraction number in early treatments. However, as treatment progressed to the 5th week of RT, nearly all the circulating blood cells were projected to receive at least 0.5 Gy (mean dose 2.2 Gy) [16]. This simulation model might explain our finding that by the 5th week of RT, nearly all circulating lymphocytes had received a low-dose (at least 0.5 Gy) of irradiation and developed resistance. The underlying mechanisms of this phenomenon are not well understood and our findings provide an important basis for further investigations.

In addition to the treatment duration, pre-RT TLCs, GTV, and MLD were real factors of out to strongly impact RI in our study. A higher GTV and MLD tended to trigger greater depletion of peripheral lymphocytes due to greater exposure of those lymphocytes to radiation. We had excluded patients who had received any other anticancer treatments besides CRT before disease progression, had used any systemic corticosteroids during RT except for pre-treatment before chemotherapy, had any ongoing infection, rheumatoid disease, or immune system disease to eliminate

| Table 4 Univariate and multivariate logistic regression of factors associated with SL during radiation treatment |
|---------------------------------|-----------------|------|
| Characteristic                  | OR (95% CI)     | P   |
| **Univariate analysis**         |                 |     |
| Sex (female vs male)            | 0.814 (0.193–3.425) | 0.778|
| Age (< 65 years vs ≥ 65 years)  | 1.124 (0.531–2.382) | 0.760|
| ECOG (0–1 vs 2)                 | 1.439 (0.621–3.334) | 0.395|
| Underlying respiratory system disease (No versus Yes) | 1.586 (0.744–3.383) | 0.233|
| Smoker (No vs others)           | 1.275 (0.518–3.139) | 0.597|
| Induction chemotherapy (No vs Yes) | 2.432 (0.963–6.142) | 0.06|
| Concurrent chemotherapy (No vs Yes) | 0.703 (0.308–1.607) | 0.404|
| Systemic Corticosteroids (No vs Yes) | 0.867 (0.357–2.106) | 0.752|
| Pre-RT TLCs (cells/μL)          | 0.998 (0.998–0.999) | < 0.001|
| GTV (< 22 cm³ vs ≥ 22 cm³)      | 3.867 (1.276–11.714) | 0.017|
| PTV (< 48 cm³ vs ≥ 48 cm³)      | 1.478 (0.464–4.706) | 0.509|
| Mean lung dose (< 1150 cGy vs ≥ 1150 cGy) | 2.720 (1.239–5.969) | 0.013|
| Heart V5 (< 6 vs ≥ 6)           | 3.704 (1.273–10.777) | 0.016|
| BED (Gy)                        | 1.026 (0.927–1.137) | 0.616|
| OTT (LTRT vs STRT)              | 0.289 (0.117–0.715) | 0.007|
| IMRT (vs 3DCRT)                 | 1.048 (0.412–2.665) | 0.922|
| HT (vs 3DCRT)                   | 0.829 (0.353–1.946) | 0.667|
| Stage IIIB (vs IIIA)            | 0.900 (0.299–2.712) | 0.851|
| Stage IIIC (vs IIIA)            | 0.884 (0.325–2.403) | 0.809|
| **Multivariate analysis**       |                 |     |
| Pre-RT TLCs (cells/μL)          | 0.998 (0.997–0.999) | < 0.001|
| GTV (< 22 cm³ vs ≥ 22 cm³)      | 6.909 (1.729–27.612) | 0.005|
| Mean lung dose (< 1150 cGy vs ≥ 1150 cGy) | 3.633 (1.349–9.787) | 0.011|
| Treatment duration (LCRT vs SCRT) | 0.322 (0.115–0.908) | 0.032|

Abbreviations: SL severe lymphopenia, OR Odds ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, RT radiotherapy, TLCs total lymphocyte counts, GTV gross tumor volume, PTV planning target volume, Heart V5 the percentage of total heart volume receiving at least 5 Gy, BED biological effective dose, OTT overall treatment time, LRRT long-term radiotherapy, STRT short-term radiotherapy, 3DCRT 3D conformal radiotherapy, IMRT Intensity modulated radiotherapy, HT Helical Tomotherapy

Note: a equivalent to approximately 60–120 mg of prednisone
b Multivariate analysis includes sex, age, ECOG, induction chemotherapy, Pre-RT TLCs, GTV, mean lung dose, Heart V5, and treatment duration
potential clinical factors influencing the lymphopenia. As for underlying respiratory system disease, our data show that it has no impact on lymphopenia. The contribution of chemotherapy to lymphopenia has been disputed [14, 34]. Our study showed that concurrent chemotherapy was not associated with SL, which was consistent with previous study [14]. Additionally, there was no difference in the median baseline TLCs or pre-RT TLCs in our study population, whether stratified by the chemotherapy regimen or cycles (all \( P > 0.05 \)). This was consistent with the notion that the choice of chemotherapy regimens and the cycles had no correlation with lymphopenia in patients with stage III NSCLC [35]. Thus, the chemotherapy regimen used in our study population did not play a major role in causing lymphopenia. Bone marrow suppression caused by chemotherapy primarily resulted in the reduction of peripheral neutrophil cell counts in our patients (data not shown). Given the potential effect of corticosteroids on circulating lymphocytes, patients who had received systemic steroids during RT were excluded from our analyses, unless steroids were used as pretreatments before chemotherapy [36, 37]. However, logistic regression analyses showed that the dose of corticosteroids (equivalent to approximately 60–120 mg of prednisone) was not associated with an increased risk of developing SL. Clinical trials for ICIs typically excluded patients who received systemic steroids exceeding 10 mg of prednisone daily (or the equivalent) [38]. Collectively, our findings indicated that the doses of transient corticosteroid administration and chemotherapy had no obvious cytotoxicity to circulating lymphocytes.

Several limitations should be noted in interpreting our results. First, the frequencies of blood tests during RT were subject to variations, although the general practice at our institution was to perform blood testing prior to, and weekly during, RT. Second, considering the TLC nadir was at the 5th week of RT, we divided patients into two groups based on whether the RT course was completed within 4 weeks. However, the small number of patients in the STRT group decreased the analysis power. For example, despite a large absolute difference in 3-year OS rates favoring the STRT group after adjustment, the data did not reach statistical significance. Third, the selection of fractionation and dosing schemes was generally based on the treating physician’s preference. Fourth, unscheduled treatment interruptions due to malfunctions prolonged the OTT. Therefore, we cannot exclude the possibility that such occurrences biased the results.

**Conclusions**

In summary, our observations suggest that changes in TLCs during definitive RT was related to treatment-duration in unresectable stage III NSCLC. TLC nadirs occurred at approximately the fifth week of RT, not upon completion of RT or upon administration of the maximal dose. Decreasing the total number of RT fractions and increasing the dose of each fraction to complete treatment within 4 weeks while maintaining same overall dose is a potential strategy to protect circulating lymphocytes and improve clinical outcomes. The clinical implications of our findings may be more pronounced in the setting of a new therapeutic strategy combining RT and immunotherapy for unresectable stage III NSCLC, particularly given the promising results observed in the PACIFIC trial. Additional large-scale prospective investigations are needed to test the potential lymphocyte-sparing of hypofractionation, particularly when used in combination with immunotherapeutic approaches.

**Additional files**

- Additional file 1: Table S1. Details of chemotherapy used in our study population (n=115). (DOCX 16 kb)
- Additional file 2: Table S2. Correlation between TLCs nadir and percentage of lung or heart dose. (DOCX 14 kb)
- Additional file 3: Table S3. Multivariate logistic regression associating baseline variables with SL during radiation treatment in subgroup patients treated with helical tomotherapy. (DOCX 14 kb)
- Additional file 4: Figure S1. Receiver operating characteristic (ROC) curves of mean lung dose and heart V5 (the percentage of total heart volume receiving at least 5 Gy). (DOCX 16 kb)

**Abbreviations**

BED: Biological effective dose; CFRT: Conventionally-fractionated radiotherapy; CRT: Chemoradiation therapy; ECOG: Eastern Cooperative Oncology Group; EQD2: Equivalent dose in 2 Gy fraction; GTV: Gross target volume; HFRT: Hypofractionated radiotherapy; HR: Hazard ratio; HT: Helical tomotherapy; ICIs: Immune checkpoint inhibitors; IQR: Interquartile range; LTRT: Long-term radiotherapy; MHD: Mean heart dose; MLD: Mean lung dose; NSCLC: Non-small cell lung cancer; OR: Odds ratio; OS: Overall survival; OTT: Overall treatment time; PET/CT: Positron emission tomography/computed tomography; PFS: Progression-free survival; PTV: Planning target volume; RIL: Radiation-induced lymphopenia; ROC: Receiver operating characteristic; RT: Radiation therapy; SL: Severe lymphopenia; STRT: Short-term radiotherapy; TCR: T cell receptor; TLCs: Total peripheral lymphocyte counts

**Acknowledgments**

Not applicable.

**Funding**

This work was supported by the Clinical research projects of Zhongshan Hospital, Fudan University (No. 2018ZSLC26) and Medical Guidance Program of the Science and Technology Commission of Shanghai Municipality (No. 18411967900).

**Availability of data and materials**

The datasets used and/or analysed during the current study available from the corresponding authors on reasonable request.

**Authors’ contributions**

ZCZ and JH designed the study. QQZ and SSD contributed to the data collection, and drafted the manuscript. GC, LXY, and SMS contributed to data collection. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The study protocol was approved by the ethics board of Zhongshan Hospital, Fudan University, and all participants gave informed consent to participate.

**Consent for publication**

Not applicable.
Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 25 February 2019 Accepted: 29 April 2019
Published online: 27 May 2019

References
1. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90.
2. Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent Chemoradiation in inoperable stage III non-small-cell lung Cancer: KCSG-LU05-04. J Clin Oncol. 2015;33:2660–6.
3. Antonia SJ, Villegas A, Daniel D, Daniel D, Vicente D, Murakami S, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med. 2017;377:1919–29.
4. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with and without consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–99.
5. Osti WF, Agoli L, Valeriani M, Falco T, Bracci S, De Sanctis V, et al. Image-guided hyperfractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;85:e157–63.
6. Kaster TS, Yaremko B, Palma DA, Rodrigues GB. Radical-intent hyperfractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer. 2015;16:1–7.
7. Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy of locally advanced non-small-cell lung cancer: a feasibility study. Radiat Oncol. 2013;8:4343–8.
8. He J, Huang Y, Chen Y, Shi S, Ye L, Hu Y, et al. Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT. J Thorac Dis. 2016;8:662–71.
9. Liu YE, Lin Q, Meng FJ, Chen XJ, Ren XC, Cao B, et al. Hyperdose accelerated hyperfractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study. Radiat Oncol. 2013;8:198.
10. Derenzi C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Modelling the immunosuppressive effect of liver SBRT by simulating the increased visceral metastases and decreased hormonal responsiveness on patients with locally advanced non-small-cell lung cancer: a randomized clinical trial. Onco Targets Ther. 2016;9:5545–52.
11. Hashimoto S, Shirato H, Hosokawa M, Nishioka T, Kuramitsu Y, Matushita K, et al. Gene induction by gamma-irradiation leads to DNA adduction fractionation in lymphocytes. J Natl Cancer Inst. 1979;63:91–9.
12. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 2013;31:860–7.
13. Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.
14. Sellins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol. 1989;142:3199–206.
15. Ku Gy, Yoon J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:767–75.
16. Meyer KK. Radiation-induced lymphocyte-immune deficiency. A factor in the increased visceral metastases and decreased hormonal responsiveness of breast cancer. Arch Surg. 1970;101:14–21.
17. Sollins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol. 1989;142:3199–206.
18. Hsu Y, Qu Y, Shang Q, Yan C, Jiang P, Wang X, et al. The clinical effects of low-dose splenic irradiation combined with chest three-dimensional conformal radiotherapy on patients with locally advanced non-small-cell lung cancer: a randomized clinical trial. Oncol Targets Ther. 2016;9:5545–52.
19. Hashimoto S, Shirato H, Hosokawa M, Nishioka T, Kuramitsu Y, Matushita K, et al. The suppression of metastases and the change in host immune response after low-dose total-body irradiation in tumor-bearing rats. Radiat Res. 1999;151:717–24.
20. Basler L, Andratschke N, Ehrbar S, Guckenberger M, Tanadini-Lang S. Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study. Radiat Oncol. 2018;13:10.
21. Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, et al. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemotherapy and radiotherapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer. 2016;4:45.
22. Campian JA, Ye X, Bock M, Grossman SA. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Investig. 2013;31:185–8.
23. Uemura T, Hida T. Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study. J Thorac Dis. 2018;10:5108–1112.
24. Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with Nivolumab. J Thorac Oncol. 2018;13:771–5.
25. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373:123–35.